PaulAHellsternMD

Gastroenterology • Crystal River, FL

Advanced Endoscopic Interventional, Esophagus Disease

Physician

Join to view full profile

Dr. Hellstern is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hellstern's full profile

Already have an account?

Office
6410 W Gulf To Lake Hwy
Crystal River, FL 34429
Phone+1 352-563-2450

Fax+1 352-563-2512

Education & Training

University of Arkansas for Medical Sciences (UAMS) College of MedicineFellowship, Gastroenterology, 1993 - 1995
Wright State UniversityResidency, Internal Medicine, 1990 - 1993
Wright State University Boonshoft School of MedicineClass of 1990

Certifications & Licensure

FL State Medical License 1995 - 2026
AR State Medical License 1993 - 1998
OH State Medical License 1991 - 1998
American Board of Internal Medicine Gastroenterology

Clinical Trials

The Plecanatide Chronic Idiopathic Constipation (CIC) Study Start of enrollment: 2011 Oct 01
Completed
Phase 2, Phase 3
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Start of enrollment: 2014 Mar 27
Completed
Phase 3
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Start of enrollment: 2014 Apr 01
Completed
Phase 3
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

107 citations
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Paul J. Pockros, Michael Fuchs, Bradley Freilich, Eugene R. Schiff, Anita Kohli
Liver International. 2019-11-01
125 citations
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Severine Vermeire, William J. Sandborn, Silvio Danese, Xavier Hébuterne, Bruce Salzberg
Lancet. 2017-07-08
17 citations
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.
Walter Reinisch, William J. Sandborn, Silvio Danese, Xavier Hébuterne, Maria Kłopocka
Journal of Crohn's & Colitis. 2021-06-22